Effect of Mukitake mushroom (Panellus serotinus) on the pathogenesis of lipid abnormalities in obese, diabetic ob/ob mice

Lipids in Health and Disease

Teruyoshi Yanagita¹  Koji Nagao²  Bungo Shirouchi⁵  Masashi Inafuku⁴  Nao Inoue³ 

[1] Department of Health and Nutrition Sciences, Nishikyushu University, Kanzaki 842-8585, Japan;Department of Applied Biochemistry and Food Science, Saga University, Saga 840-8502, Japan;Department of Food Function and Health, Tohoku University, Miyagi, 981-8555, Japan;Department of Mangroves and Bio-resources, University of the Ryukyus, Okinawa, 903-0213, Japan;Department of Bioscience and Biotechnology, Kyushu University, Fukuoka, 812-8581, Japan

关键词: ob/ob mice;    Nonalcoholic fatty acid disease;    Atherogenic index;    Panellus serotinus;   

Others  :  1160074
DOI  :  10.1186/1476-511X-12-18

 received in 2012-12-30, accepted in 2013-02-03,  发布年份 2013

【 摘 要 】

Background

Various mushrooms have been used in folk medicine for the treatment of lifestyle diseases in eastern countries, and several compounds that modulate the immune system, lower blood lipid levels, and inhibit tumor and viral action have been isolated. The fruiting body of Panellus serotinus (Mukitake) is recognized in Japan as one of the most delicious edible mushrooms, and previous studies have demonstrated that the dietary intake of powdered whole Mukitake or Mukitake extracts prevents the development of non-alcoholic fatty liver disease (NAFLD) in leptin-resistant db/db mice. In the present study, we evaluated the effect of the Mukitake diet on the pathogenesis of metabolic disorders in leptin-deficient ob/ob mice.

Results

After 4 weeks of feeding, hepatomegaly, hepatic lipid accumulation, and elevated hepatic injury markers in the serum were markedly alleviated in Mukitake-fed ob/ob mice compared with control mice. Moreover, the mild hyperlipidemia in control ob/ob mice was attenuated and the elevated atherogenic index was reduced in Mukitake-fed ob/ob mice. These effects were partly attributable to the suppression of hepatic lipogenic enzyme activity due to the Mukitake diet.

Conclusion

The current results showed that Mukitake supplementation is beneficial for the alleviation of NAFLD and dyslipidemia in obese, diabetic ob/ob mice.

【 授权许可】

   
2013 Inoue et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Chang R: Functional properties of edible mushrooms. Nutr Rev 1996, 54:S91-93.
• [2]Wasser SP: Medical mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 2002, 60:258-274.
• [3]Ukawa Y, Furuichi Y, Kokean Y, Nishii T, Hisamatsu M: Effect of hatakeshimeji (Lyophyllum decastes Sing.) mushroom on serum lipid levels in rats. J Nutr Sci Vitaminol 2002, 8:73-76.
• [4]Zaidman B-Z, Yassin M, Mahajna J, Wasser SP: Medical mushroom modulators of molecular targets as cancer therpeutics. Appl Microbiol Biotechnol 2005, 67:453-468.
• [5]Watanabe A, Kobayashi M, Hayashi S, Kodama D, Isoda K, Kondoh M, Kawase M, Tamesada M, Yagi K: Protection against D-galactosamine-induced acute liver injury by oral administration of extracts from lentinus edodes mycelia. Biol Pharm Bull 2006, 29:1651-1654.
• [6]Ukawa Y, Izumi Y, Ohbuchi T, Takahashi T, Ikemizu S, Kojima Y: Oral administration of the extract from Hatakeshimeji (Lyophyllum decastes Sing.) mushroom inhibits the development of atopic dermatitis-like skin lesions in NC/Nga mice. J Nutr Sci Vitaminol 2007, 53:293-196.
• [7]Nagamori N: Simple equipment cultivation of Panellus serotinus. Kyushu J Forrest Res 2007, 60:146-148.
• [8]Kissebah AH, Krakower GR: Regional adiposity and morbidity. Physiol Rev 1994, 74:761-811.
• [9]Formiguera X, Canton A: Obesity: epidemiology and clinical aspects. Best Pract Res Clin Gastroenterol 2004, 18:1125-1146.
• [10]Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y: Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007, 22:1086-1091.
• [11]Harrison SA, Diehl AM: Fat and the liver—a molecular overview. Semin Gastrointest Dis 2002, 13:3-16.
• [12]Youssef W, McCullough AJ: Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis 2002, 13:17-30.
• [13]Nagao K, Yanagita T: Bioactive lipids in metabolic syndrome. Prog Lipid Res 2008, 47:127-146.
• [14]Hummel KP, Dickie MM, Coleman DL: Diabetes, a new mutation in the mouse. Science 1966, 153:1127-1128.
• [15]Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
• [16]Trak-Smayra V, Paradis V, Massart J, Nasser S, Jebara V, Fromenty B: Pathology of the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie diet. Int J Exp Pathol 2011, 92:413-421.
• [17]Nagao K, Inoue N, Inafuku M, Shirouchi B, Morooka T, Nomura S, Nagamori N, Yanagita T: Mukitake mushroom (Panellus serotinus) alleviates nonalcoholic fatty liver disease through the suppression of monocyte chemoattractant protein-1 production in db/db mice. J Nutr Biochem 2010, 21:418-423.
• [18]Inafuku M, Nagao K, Nomura S, Shirouchi B, Inoue N, Nagamori N, Nakayama H, Toda T, Yanagita T: Protective effects of fractional extracts from Panellus serotinus on nonalcoholic fatty liver disease in obese, diabetic db/db mic. Br J Nutr 2012, 107:639-646.
• [19]American Institute of Nutrition: Report of the American institute of nutrition ad hoc committee on standards for nutritional studies. J Nutr 1977, 107:1340-1348.
• [20]Wang YM, Nagao K, Ujino Y, Sakata K, Higa K, Inoue N, Yanagita T: Short-term feeding of conjugated linoleic acid does not induce hepatic steatosis in C57BL/6J mice. J Nutr Sci Vitaminol 2005, 51:440-444.
• [21]Shirouchi B, Nagao K, Inoue N, Furuya K, Koga S, Matsumoto H, Yanagita T: Dietary phosphatidylinositol prevents the development of nonalcoholic fatty liver disease in Zucker (fa/fa) rats. J Agric Food Chem 2008, 56:2375-2379.
• [22]Ikeda I, Konno R, Shimizu T, Ide T, Takahashi N, Kawada T, Nagao K, Inoue N, Yanagita T, Hamada T, Morinaga Y, Tomoyori H, Imaizumi K, Suzuki K: Campest-5-en-3-one, an oxidized derivative of campesterol, activates PPARα, promotes energy consumption and reduces visceral fat deposition in rats. Biochim Biophys Acta 2006, 1760:800-807.
• [23]Wang YM, Nagao K, Inoue N, Ujino Y, Shimada Y, Nagao T, Iwata T, Kamegai T, Yamauchi-Sato Y, Yanagita T: Isomer-specific anti-obese and hypolipidemic properties of conjugated linoleic acid in obese OLETF rats. Biosci Biotechnol Biochem 2006, 70:355-362.
• [24]Nagao K, Yamano N, Shirouchi B, Inoue N, Murakami S, Sasaki T, Yanagita T: Effects of citrus auraptene (7-geranyloxycoumarin) on hepatic lipid metabolism in vitro and in vivo. J Agric Food Chem 2010, 58:9028-9032.
• [25]Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG: Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999, 84:1513-1517.
• [26]Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
• [27]Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M: Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
• [28]Matsuzawa Y: Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006, 3:35-42.
• [29]Day CP, James OF: Steatohepatitis: a tale of two “hits”? Gastroenterology 1998, 114:842-845.
• [30]Matsuzawa Y: Overproduction of very Low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:1225-1236.